ZYMAR
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Mar 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYMAR is an ophthalmic antibiotic solution approved in 2003 for bacterial eye infections. Administered as eye drops, it represents a small-molecule topical therapy for ocular bacterial pathogens. The exact mechanism of action and specific indications are not disclosed in available data.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30), suggesting team focus is shifting toward lifecycle management and preparation for generic entry.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Effectiveness Study of Zymar Versus Vigamox for Preoperative Sterilization of the Ocular Surface After Loading Dose
Started Jun 2006
40 enrolled
Eye InfectionInfection
Career Relevance
ZYMAR currently shows zero linked job openings, reflecting its mature, declining lifecycle stage. Careers on this product are oriented toward defensive commercial strategies, cost optimization, and portfolio transition planning rather than growth or launch initiatives.
Brand Manager
Worked on ZYMAR at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.